Supplement
Zeaxanthin
The junior partner in the eye formula, graded on the pair's evidence and labeled as such.
Zeaxanthin is the second macular pigment, chemically a near-twin of lutein, concentrated at the center of the macula (the fovea) where visual acuity lives. We grade Zeaxanthin B- on evidence and B- for worth-it at about $10-18 per month.
Evidence
Worth it
Typical cost: $10-18/month
What it does
Zeaxanthin is the second macular pigment, chemically a near-twin of lutein, concentrated at the center of the macula (the fovea) where visual acuity lives. It is obtained from corn, orange peppers, and eggs, in much smaller dietary amounts than lutein, and is studied and sold almost exclusively as lutein's partner in the AREDS2 formula.
What the research says
Shares the AREDS2 formula evidence with lutein; has almost no independent trial record of its own
Evidence: moderate. Every major finding for zeaxanthin comes from trials where it was given with lutein (10 mg lutein + 2 mg zeaxanthin in AREDS2 and its 10-year follow-up: HR 0.85 for progression to late AMD versus the beta-carotene formula). No trial isolates zeaxanthin's contribution. Grading it separately is this library's discipline; the honest statement is that the pair is the intervention and this is the junior partner.
Concentrates at the very center of the macula, where lutein is scarcer
Evidence: emerging. Anatomy is the argument for including it at all: zeaxanthin dominates the central fovea while lutein dominates the periphery, and dietary intake of zeaxanthin specifically is very low (corn, orange peppers, and egg yolk are the main sources). Plausible, anatomical, and untested as an isolated claim.
Zeaxanthin inherits the AREDS2 verdict, and the inheritance is disclosed rather than hidden: the trial program is strong, the pair is the unit of evidence, and the anatomical case for zeaxanthin's specific role (it dominates the central macula) is coherent. Graded B- alongside lutein, because separating them would pretend to a precision the trials never measured, and grading it lower would punish it for a trial design the field chose for good anatomical reasons.
The week's longevity and biohacking news.
This grade for Zeaxanthin rests on the record above. When a new result changes that record, the grade changes with it, and the Thursday email is where the change lands first: the week's longevity and biohacking news, in plain English, linked back to the reasoning on this page.
The week's longevity and biohacking news. Every story graded against the evidence. Free. Unsubscribe anytime.
Every grade follows a published rubric, and sponsors never change one. When the evidence moves a grade, Thursday is where you hear it first, before you renew a stack that stopped earning its cost.
Is it worth it?
Evidence (B-) is inherited from the AREDS2 pair and clears the leaderboard floor; the worth-it grade is the derived value at this price: about $14 a month at the studied dose. Derived from the October 2026 worth-it model.
Typical cost
$10-18/month
Common form, not a brand recommendation
Dosage context established
The studied dose is 2 mg/day alongside 10 mg of lutein, the AREDS2 ratio, taken with fat-containing food. Standalone zeaxanthin products dosed far higher have no trial basis; more is not a studied strategy here.
Worth-it leaderboard
Zeaxanthin sits outside the worth-it top 20.
Zeaxanthin sits outside the current top 20 on the gated leaderboard. The leaders below clear an evidence floor of B- before price counts at all, so cheap alone never earns a rank.
See the full worth-it leaderboard →
When the evidence moves a grade, this ranking moves with it. Thursday is where you hear it first.
Safety notes
Shares lutein's clean trial safety record, including no lung-cancer signal in smokers across ten years of AREDS2 follow-up, the property that displaced beta-carotene from eye formulas. Harmless skin yellowing can occur at high carotenoid intakes. No significant interactions documented.
Longevity Lab Report
Zeaxanthin news. Graded when it happens.
The grade on this page stays free. The email carries the news on zeaxanthin: expert moves, dose changes, and what is working, in plain English every Thursday.
Changelog
Last updated 2026-10-23
- 2026-10-23|Graded with its pair partner lutein from the AREDS2 program. The record states plainly that no trial separates zeaxanthin's effect from lutein's, and that its grade is inherited from the pair at the pair's dose and ratio.
- 2026-10-23|Listed under longevity, matching the pair's graded role in preserving vision in aging eyes; the library has no eye-health goal.